Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 0.49 |
| ▸ | RAF1 | P04049 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1233204 | 0.82 | MAPK14 (0.72) | MAPK14RAF1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL12845323 | 0.82 | MAPK14 (0.70) | MAPK14RAF1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL12845322 | 0.81 | MAPK14 (0.66) | MAPK14RAF1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL12845498 | 0.78 | MAPK14 (0.68) | MAPK14RAF1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL12845656 | 0.76 | MAPK14 (0.72) | MAPK14RAF1 | |
| SCHEMBL1233613 | 0.74 | MAPK14 (0.72) | MAPK14RAF1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL12845655 | 0.70 | MAPK14 (0.70) | MAPK14RAF1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL12845418 | 0.70 | MAPK14 (0.66) | MAPK14RAF1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1233836 | 0.67 | MAPK14 (0.82) | MAPK14RAF1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1235034 | 0.66 | MAPK14 (1.00) | MAPK14RAF1CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053936-A1 | SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDOL]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | ALMIRALL, S.A. (ES) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053936-A1 | SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDOL]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K7 | MAPK14 25/4885RAF1 71/4885CYP1A2 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.